Clinical trials: Meropenem
Pancreatitis
Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g IV meropenem given during the induction period of anesthesia.
- Trial name
- NCT00318994
- Testing
- Meropenem
- Where
- Colombia
- Volunteers
- 6 people
- Sponsor
- Pfizer
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Pediatric Patients Receiving Venoarterial Extracorporeal Membrane Oxygenation
Population Pharmacokinetics of Vancomycin, Meropenem, Milrinone, Dexmedetomidine and Fentanyl in Pediatric Patients During Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation (ECMO) has been used primarily in newborns since it was first successfully implemented in the 1970s, and has recently increased use in infants and young children.
- Trial name
- NCT04701099
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Yonsei University
Sepsis, Bacterial Infection
EFFICACY OF PROLONGED INFUSION MEROPENEM IN CRITICALLY ILL PAEDIATRIC INTENSIVE CARE PATIENTS
As a broad-spectrum carbapenem, meropenem is one of the most commonly used antibiotics for critically ill pediatric patients who have severe infections.
- Trial name
- NCT07122596
- Testing
- Meropenem Infusion
- Where
- Pakistan
- Volunteers
- 150 people
- Sponsor
- Pakistan Navy Station Shifa Hospital
Necrotizing Enterocolitis, Intra-abdominal Infection
Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections
Meropenem is an antibiotic that is commonly used to treat serious infections. Although it is used in premature and young infants, the correct dose is not known.
- Trial name
- NCT00621192
- Testing
- meropenem
- Where
- 26 sites in United States
- Volunteers
- 200 people
- Sponsor
- The Emmes Company, LLC
Gram Negative Infections
A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
The goal of this clinical trial is to assess the pharmacokinetic (PK) and safety and tolerability of Vaborem (fixed combination of meropenem and vaborbactam) in the paediatric population aged from birth to < 18 years with…
- Trial name
- NCT06828848
- Testing
- Meropenem plus vaborbactam
- Where
- 22 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Menarini Group
Enteric Fever
Meropenem vs Azithromycin Efficacy in Case XDR Enteric Fever
1. Primary Objective: o To evaluate the efficacy of intravenous azithromycin compared with meropenem in the treatment of extensively drug-resistant (XDR) enteric fever. 2.
- Trial name
- NCT07314281
- Testing
- Azithromycin, Meropenem Injection
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Indus Hospital and Health Network
Acute Pyelonephritis, Complicated Urinary Tract Infection
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract…
- Trial name
- NCT06672978
- Testing
- Meropenem-Vaborbactam, Antibiotics
- Where
- 26 sites in United States, Bulgaria and 4 more
- Volunteers
- 66 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia
Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. Baumannii
Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will…
- Conditions
- Carbapenem Resistant Bacterial Infection, Acinetobacter Bacteremia, Acinetobacter Pneumonia
- Trial name
- CASCADE (NCT05922124)
- Testing
- Cefiderocol, Ampicillin-sulbactam, Colistin
- Where
- 3 sites in Israel
- Volunteers
- 734 people
- Sponsor
- Rambam Health Care Campus